Next Article in Journal
Prenylated Flavonoids from Cudrania tricuspidata Suppress Lipopolysaccharide-Induced Neuroinflammatory Activities in BV2 Microglial Cells
Next Article in Special Issue
Induced Pluripotent Stem Cell Therapies for Cervical Spinal Cord Injury
Previous Article in Journal
Deletion of Phytochelatin Synthase Modulates the Metal Accumulation Pattern of Cadmium Exposed C. elegans
Previous Article in Special Issue
Chemically Induced Reprogramming of Somatic Cells to Pluripotent Stem Cells and Neural Cells
Review

Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells

Department of Animal Biotechnology, Animal Resources Research Center, and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, Gwangjin-gu, Seoul 05029, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Wenbin Deng
Int. J. Mol. Sci. 2016, 17(2), 256; https://doi.org/10.3390/ijms17020256
Received: 3 January 2016 / Revised: 5 February 2016 / Accepted: 15 February 2016 / Published: 19 February 2016
Diabetes mellitus (DM) is a widespread metabolic disease with a progressive incidence of morbidity and mortality worldwide. Despite extensive research, treatment options for diabetic patients remains limited. Although significant challenges remain, induced pluripotent stem cells (iPSCs) have the capacity to differentiate into any cell type, including insulin-secreting pancreatic β cells, highlighting its potential as a treatment option for DM. Several iPSC lines have recently been derived from both diabetic and healthy donors. Using different reprogramming techniques, iPSCs were differentiated into insulin-secreting pancreatic βcells. Furthermore, diabetes patient-derived iPSCs (DiPSCs) are increasingly being used as a platform to perform cell-based drug screening in order to develop DiPSC-based cell therapies against DM. Toxicity and teratogenicity assays based on iPSC-derived cells can also provide additional information on safety before advancing drugs to clinical trials. In this review, we summarize recent advances in the development of techniques for differentiation of iPSCs or DiPSCs into insulin-secreting pancreatic β cells, their applications in drug screening, and their role in complementing and replacing animal testing in clinical use. Advances in iPSC technologies will provide new knowledge needed to develop patient-specific iPSC-based diabetic therapies. View Full-Text
Keywords: diabetes mellitus; induced pluripotent stem cells; insulin-secreting β cells; cell-based drug screening; iPSC-based diabetic therapy diabetes mellitus; induced pluripotent stem cells; insulin-secreting β cells; cell-based drug screening; iPSC-based diabetic therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Kawser Hossain, M.; Abdal Dayem, A.; Han, J.; Kumar Saha, S.; Yang, G.-M.; Choi, H.Y.; Cho, S.-G. Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells. Int. J. Mol. Sci. 2016, 17, 256. https://doi.org/10.3390/ijms17020256

AMA Style

Kawser Hossain M, Abdal Dayem A, Han J, Kumar Saha S, Yang G-M, Choi HY, Cho S-G. Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells. International Journal of Molecular Sciences. 2016; 17(2):256. https://doi.org/10.3390/ijms17020256

Chicago/Turabian Style

Kawser Hossain, Mohammed, Ahmed Abdal Dayem, Jihae Han, Subbroto Kumar Saha, Gwang-Mo Yang, Hye Y. Choi, and Ssang-Goo Cho. 2016. "Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells" International Journal of Molecular Sciences 17, no. 2: 256. https://doi.org/10.3390/ijms17020256

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop